Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557918 · ClinicalTrials.gov registry record · Phase 2
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
A Phase 2 study, sponsored by Matthew Galsky.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03557918 is a Phase 2 study that has completed, run by Matthew Galsky. The registered enrollment target is 26 participants.
The verdict
NCT03557918, a Phase 2 study, has completed, sponsored by Matthew Galsky.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase II trial designed to estimate the activity of single agent tremelimumab in subjects with metastatic urothelial cancer with disease progression despite prior treatment with PD-1/PD-L1 blockade. The primary endpoint is objective response rate and the study will employ a Simon's 2-stage design.
Interventions
- DRUG Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2023-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03557918
The ClinicalTrials.gov registry entry for NCT03557918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tremelimumab is the first listed.
NCT03557918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03557918 about?
NCT03557918 is a clinical study titled "Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer". This is a phase II trial designed to estimate the activity of single agent tremelimumab in subjects with metastatic urothelial cancer with disease progression despite prior treatment with PD-1/PD-L1 blockade. The primary endpoint is objective response rate and the study will employ a Simon's 2-stage...
What is the current status of trial NCT03557918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2018-11-12. Estimated completion is 2023-06-07.
What interventions are being tested in trial NCT03557918?
The interventions under investigation include: Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03557918?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.